Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on June 2, 2008
Japanese Journal of Clinical Oncology 2008 38(6):426-431; doi:10.1093/jjco/hyn041
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/6/426    most recent
hyn041v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chin, K.
Right arrow Articles by Hatake, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chin, K.
Right arrow Articles by Hatake, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2008). Published by Oxford University Press. All rights reserved

Irinotecan Plus Cisplatin for Therapy of Small-cell Carcinoma of the Esophagus: Report of 12 Cases from Single Institution Experience

Keisho Chin1, Satoshi Baba1, Hisashi Hosaka1, Akiyoshi Ishiyama1, Nobuyuki Mizunuma1, Eiji Shinozaki1, Mitsukuni Suenaga1, Takuyo Kozuka1, Yasuyuki Seto1, Noriko Yamamoto2 and Kiyohiko Hatake1

1 Cancer Institute Hospital of Japanese Foundation for Cancer Research
2 Department of Pathology, Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan

For reprints and all correspondence: Keisho Chin, 3-10-6 Ariake Koutou-ku, Tokyo 135-8550, Japan. E-mail: kchin{at}jfcr.or.jp

Received January 14, 2008; accepted May 5, 2008

Background: Esophageal small-cell cancer is a rare disease, and standard therapy has not yet been established.

Methods: A total of 12 esophageal small-cell carcinoma patients were treated with CPT-11 (70 mg/m2) on Days 1 and 15 and CPT-11 plus CDDP (80 mg/m2) on Day 1 with each cycle repeated every 4 weeks at our institution.

Results: A total of 46 chemotherapy courses were given (median, 3.5). There were two complete responses and eight partial responses. The median survival time was 417 (97–1626) days, and three patients were still alive for >40 months. Grade 4 neutropenia was observed in two patients, Grade 4 anemia in one patient, Grade 3–4 diarrhea in three patients and Grade 3–4 hyponatremia in three patients. Other adverse reactions seen were mild with no treatment-related deaths observed.

Conclusions: To our knowledge, this is the first report of the series of more than 10 patients with small-cell carcinoma of the esophagus treated with the same chemotherapy regimen. The combination of CPT-11 and CDDP appears to be effective therapy of this disease with acceptable toxicity profile. We believe that this regimen is one of the options to be considered for treatment of esophageal small-cell carcinoma.

Key Words: small-cell carcinoma • esophageal cancer • chemotherapy • CPT-11 • cisplatin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.